60 Degrees Pharma To Expand ARAKODA Sales And Marketing, Adding Reps, GoodRx Partnership And Enhanced Digital Campaign

• 6-month commercial pilot demonstrated increasing demand among prescribers
• Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign
• Additional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company's breakthrough therapy designation request
  
   

WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the planned expansion of the Company's sales and marketing initiatives after encouraging results from a 6-month commercial pilot that showed an overall increase in product sales. The positive outcome points to increasing market demand for ARAKODA® among prescribers.

In response to the encouraging results, the Company will implement several strategic initiatives designed to expand market reach and accelerate ARAKODA sales in 2026:

• Inside Sales Team Expansion:
  
  The number of inside sales representatives will increase to deepen outreach across prescribers, strengthen provider relationships, and enhance product education and support.
• GoodRx Partnership for Broader Offer Visibility:
  
  The Company will engage with GoodRx to provide wider coverage of its point-of-sale (POS) ARAKODA offer, enabling patients and prescribers to access savings information more efficiently.
• Enhanced Digital "Surround Sound" Campaign:
  
   

Building on initial successes, the ARAKODA Marketing team will continue to optimize its integrated digital marketing campaign, ensuring high-frequency awareness, relevant targeting, and sustained engagement across prescriber audiences.